YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Wins and Deals at JP Morgan


January 13, 2014 | Luke Timmerman has a good roundup of the buzz and trends at the JP Morgan Healthcare Conference. The conference is still ongoing, but the winners so far appear to be Intercept Pharmaceuticals, a small New York company with a liver damage drug so successful that trials were stopped early; immuno-oncology as a field; rare diseases as targets; and Alnylam. Alnylam signed a deal with Genzyme to the tune of $700 million, and immediately used some of its new cash flow to buy RNAi technologies and Sirna Therapeutics from Merck. Xconomy
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.